Case Evaluation
Over $150 Million Collected for Plantiffs in 2011


Date posted: 4/18/2012

Since the FDA announced in June of 2011 that the diabetes drug Actos may be linked to bladder cancer, thousands of patients affected by the disease have come forward to pursue legal action against Takeda Pharmaceuticals over the defective drug.

The FDA warning came after a French study was published finding that long-term use of Actos could heighten the risk of developing bladder cancer by as much as 40%.

Both Germany and France have banned new prescriptions of the drug. Regulators in Canada, the United States and the rest of Europe have issued warnings, but left the drug on the market.

In December, a federal Judicial Panel ruled that, instead of one Actos class action lawsuit, the hundreds or thousands of individual lawsuits will be consolidated under a special court in Louisiana. Bloomberg News recently reported as many as 10,000 lawsuits may eventually be filed. 

On March 12, 2012, Judge Doherty appointed the managing lawyers for the Actos litigation, which signals that the start of the first lawsuits may not be far off.

The Actos cases will be handled in a unique Multi-District Litigation court, which can be more complex than traditional lawsuits. Therefore, it is important that anyone affected choose a lawyer who has experience with defective drug mass tort cases.

The Actos Resource Center only works with top defective drug lawyers who are qualified for Actos cases.

Contact us today for more information on the research, warnings, side effects and legal news pertaining to the drug Actos.

Facebook Twitter Youtube